vs
HERITAGE FINANCIAL CORP（HFWA）与Travere Therapeutics, Inc.（TVTX）财务数据对比。点击上方公司名可切换其他公司
Travere Therapeutics, Inc.的季度营收约是HERITAGE FINANCIAL CORP的2.0倍（$129.7M vs $66.3M），Travere Therapeutics, Inc.同比增速更快（73.4% vs 16.3%），过去两年Travere Therapeutics, Inc.的营收复合增速更高（77.0% vs 16.8%）
总部位于美国华盛顿州的区域性金融控股公司，面向太平洋西北地区的当地社群提供服务，核心业务涵盖商业与零售银行服务，包含存款产品、中小企业贷款、住房抵押贷款、个人信贷及财富管理解决方案，核心客群为中小微企业及个人客户。
Travere Therapeutics是一家全球生物制药企业，专注于为罹患罕见、严重且危及生命疾病的患者开发和商业化创新疗法，核心覆盖罕见肾病、肝病及代谢疾病领域，业务覆盖北美、欧洲等主要市场。
HFWA vs TVTX — 直观对比
营收规模更大
TVTX
是对方的2.0倍
$66.3M
营收增速更快
TVTX
高出57.1%
16.3%
两年增速更快
TVTX
近两年复合增速
16.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.3M | $129.7M |
| 净利润 | $22.2M | — |
| 毛利率 | — | 98.0% |
| 营业利润率 | 38.7% | -25.0% |
| 净利率 | 33.5% | — |
| 营收同比 | 16.3% | 73.4% |
| 净利润同比 | 86.4% | — |
| 每股收益（稀释后） | $0.65 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HFWATVTX
| Q4 25 | $66.3M | $129.7M | ||
| Q3 25 | $65.7M | $164.9M | ||
| Q2 25 | $56.5M | $114.4M | ||
| Q1 25 | $57.6M | $81.7M | ||
| Q4 24 | $57.1M | $74.8M | ||
| Q3 24 | $54.8M | $62.9M | ||
| Q2 24 | $56.4M | $54.1M | ||
| Q1 24 | $48.6M | $41.4M |
净利润HFWATVTX
| Q4 25 | $22.2M | — | ||
| Q3 25 | $19.2M | $25.7M | ||
| Q2 25 | $12.2M | $-12.8M | ||
| Q1 25 | $13.9M | $-41.2M | ||
| Q4 24 | $11.9M | — | ||
| Q3 24 | $11.4M | $-54.8M | ||
| Q2 24 | $14.2M | $-70.4M | ||
| Q1 24 | $5.7M | $-136.1M |
毛利率HFWATVTX
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
营业利润率HFWATVTX
| Q4 25 | 38.7% | -25.0% | ||
| Q3 25 | 34.0% | 15.1% | ||
| Q2 25 | 25.6% | -11.1% | ||
| Q1 25 | 28.1% | -52.2% | ||
| Q4 24 | 28.6% | -81.2% | ||
| Q3 24 | 23.8% | -89.3% | ||
| Q2 24 | 28.4% | -125.1% | ||
| Q1 24 | 14.1% | -336.5% |
净利率HFWATVTX
| Q4 25 | 33.5% | — | ||
| Q3 25 | 29.2% | 15.6% | ||
| Q2 25 | 21.6% | -11.1% | ||
| Q1 25 | 24.2% | -50.4% | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 20.8% | -87.1% | ||
| Q2 24 | 25.1% | -130.1% | ||
| Q1 24 | 11.8% | -328.9% |
每股收益（稀释后）HFWATVTX
| Q4 25 | $0.65 | $0.04 | ||
| Q3 25 | $0.55 | $0.28 | ||
| Q2 25 | $0.36 | $-0.14 | ||
| Q1 25 | $0.40 | $-0.47 | ||
| Q4 24 | $0.34 | $-0.71 | ||
| Q3 24 | $0.33 | $-0.70 | ||
| Q2 24 | $0.41 | $-0.91 | ||
| Q1 24 | $0.16 | $-1.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.1M | $93.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $921.5M | $114.8M |
| 总资产 | $7.0B | $605.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HFWATVTX
| Q4 25 | $233.1M | $93.0M | ||
| Q3 25 | $245.5M | $110.9M | ||
| Q2 25 | $254.1M | $75.2M | ||
| Q1 25 | $248.7M | $61.9M | ||
| Q4 24 | $117.1M | $58.5M | ||
| Q3 24 | $175.6M | $36.4M | ||
| Q2 24 | $113.8M | $32.3M | ||
| Q1 24 | $189.6M | $43.3M |
股东权益HFWATVTX
| Q4 25 | $921.5M | $114.8M | ||
| Q3 25 | $904.1M | $73.6M | ||
| Q2 25 | $888.2M | $32.7M | ||
| Q1 25 | $881.5M | $32.8M | ||
| Q4 24 | $863.5M | $59.1M | ||
| Q3 24 | $874.5M | $-30.5M | ||
| Q2 24 | $850.5M | $15.1M | ||
| Q1 24 | $847.6M | $74.1M |
总资产HFWATVTX
| Q4 25 | $7.0B | $605.2M | ||
| Q3 25 | $7.0B | $538.6M | ||
| Q2 25 | $7.1B | $555.3M | ||
| Q1 25 | $7.1B | $548.8M | ||
| Q4 24 | $7.1B | $594.1M | ||
| Q3 24 | $7.2B | $504.4M | ||
| Q2 24 | $7.1B | $551.1M | ||
| Q1 24 | $7.1B | $663.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.8M | $60.7M |
| 自由现金流经营现金流 - 资本支出 | $85.7M | — |
| 自由现金流率自由现金流/营收 | 129.1% | — |
| 资本支出强度资本支出/营收 | 13.8% | — |
| 现金转化率经营现金流/净利润 | 4.26× | — |
| 过去12个月自由现金流最近4个季度 | $149.0M | — |
8季度趋势，按日历期对齐
经营现金流HFWATVTX
| Q4 25 | $94.8M | $60.7M | ||
| Q3 25 | $25.1M | $14.3M | ||
| Q2 25 | $22.5M | $5.0M | ||
| Q1 25 | $19.3M | $-42.2M | ||
| Q4 24 | $64.5M | $-35.7M | ||
| Q3 24 | $24.2M | $-42.5M | ||
| Q2 24 | $6.8M | $-40.2M | ||
| Q1 24 | $12.9M | $-119.0M |
自由现金流HFWATVTX
| Q4 25 | $85.7M | — | ||
| Q3 25 | $24.4M | $14.2M | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $61.0M | — | ||
| Q3 24 | $23.2M | — | ||
| Q2 24 | $6.0M | $-40.3M | ||
| Q1 24 | $12.0M | — |
自由现金流率HFWATVTX
| Q4 25 | 129.1% | — | ||
| Q3 25 | 37.1% | 8.6% | ||
| Q2 25 | 37.0% | — | ||
| Q1 25 | 31.4% | — | ||
| Q4 24 | 107.0% | — | ||
| Q3 24 | 42.4% | — | ||
| Q2 24 | 10.6% | -74.5% | ||
| Q1 24 | 24.7% | — |
资本支出强度HFWATVTX
| Q4 25 | 13.8% | — | ||
| Q3 25 | 1.0% | 0.1% | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 6.1% | — | ||
| Q3 24 | 1.7% | 0.0% | ||
| Q2 24 | 1.5% | 0.2% | ||
| Q1 24 | 1.8% | 0.0% |
现金转化率HFWATVTX
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.31× | 0.56× | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | 1.38× | — | ||
| Q4 24 | 5.41× | — | ||
| Q3 24 | 2.12× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 2.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HFWA
暂无分部数据
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
